Second-generation GLP-1-based peptide therapies now achieve 15-25% weight loss — results once thought only possible through bariatric surgery — thanks to advances in fatty acid technology and multi-target agonist design.
15-25% weight lossThe range of body weight reduction achieved by second-generation GLP-1-based peptide therapies, previously thought achievable only through bariatric surgery
What the researchers found
GLP-1-based peptide therapeutics have achieved 15-25% weight loss in obesity treatment, a level previously thought achievable only through bariatric surgery. This breakthrough was driven by two key innovations: fatty acid conjugation technology combined with peptide backbone engineering to enable once-weekly dosing, and the development of unimolecular dual and poly-agonists that activate multiple hormone receptor pathways beyond GLP-1 alone.
The review highlights that while these second-generation therapies offer excellent efficacy and safety, significant barriers remain in scaling up manufacturing infrastructure to meet global demand for hundreds of millions of potential patients.
Why it matters
Obesity affects hundreds of millions of people worldwide and is a leading risk factor for diabetes, cardiovascular disease, and many other conditions. The fact that peptide drugs can now achieve weight loss results comparable to surgery — without going under the knife — represents a paradigm shift in how we treat this condition. Understanding the design innovations behind these drugs helps contextualize the rapid pace of development in this space.
How the study worked
This is a narrative review article that synthesizes the current landscape of peptide-based obesity therapeutics. The author examines the evolution from first-generation GLP-1 receptor agonists to second-generation peptides, analyzing the design principles, manufacturing innovations, and clinical outcomes that have driven progress in the field.
What this study cannot tell us
As a review article, this paper synthesizes existing research rather than presenting new experimental data. The 15-25% weight loss figures represent the best outcomes from clinical trials and may not reflect real-world results across diverse populations. The review focuses primarily on the drug design perspective and does not deeply address long-term safety data, cost-effectiveness, or the psychological and behavioral aspects of obesity treatment.
How to read the evidence
This is an expert review article synthesizing clinical trial data and design principles for peptide-based obesity therapeutics. While it draws on high-quality evidence from clinical trials, it is itself a secondary source providing expert interpretation rather than new primary data.
When this study was published
Published in 2026, this is an extremely current review that captures the latest developments in peptide-based obesity therapeutics, including second-generation agents currently in development or recently approved.
The bigger picture
This review captures a pivotal moment in medicine where peptide therapeutics are transitioning from niche treatments to mainstream solutions for one of the world's most prevalent health conditions. The innovations in peptide engineering described here — fatty acid conjugation, backbone modifications, and multi-receptor targeting — are design principles being applied across the entire peptide drug development field, not just obesity. The manufacturing scale-up challenge highlighted by the author is arguably the biggest bottleneck in making these treatments accessible globally.
Questions still open
- How quickly can manufacturing infrastructure scale to meet global demand for peptide-based obesity treatments?
- Will poly-agonist peptides targeting three or more hormone pathways further improve weight loss outcomes beyond 25%?
- What are the long-term safety implications of sustained use of these second-generation peptide therapeutics?
Common questions
What makes second-generation peptide obesity drugs better than earlier versions?
Why can't everyone who needs these drugs get them right now?
Read the original research
Advancing obesity treatments through innovations in the design and manufacturing of therapeutic peptides.
Expert opinion on drug discovery, 21(1), 49-72
Citation
Østergaard, Søren. (2026). Advancing obesity treatments through innovations in the design and manufacturing of therapeutic peptides.. Expert opinion on drug discovery, 21(1), 49-72. https://doi.org/10.1080/17460441.2025.2601113